Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2014

01-02-2014 | Research Article

Treatment beliefs, illness perceptions, and non-adherence to antiretroviral therapy in an ethnically diverse patient population

Authors: Mary Gunther, Michelle Foisy, Stanley Houston, Lisa Guirguis, Christine Hughes

Published in: International Journal of Clinical Pharmacy | Issue 1/2014

Login to get access

Abstract

Background Ethnic diversity is increasingly encountered in the HIV-infected population in North America, and it is unknown if beliefs surrounding illness and treatment vary among different ethnic groups. Objective Our objectives were to determine whether self-reported adherence, illness perceptions and treatment beliefs regarding HIV differ based on ethnicity. Setting This study was conducted during outpatient HIV clinic visits between March 1, 2010 and April 30, 2010 at two hospital-based clinics in Edmonton, AB, Canada. Methods A cross-sectional sample of 65 patients on antiretroviral therapy (34 Caucasian, 23 Aboriginal, and 8 from other ethnic groups) attending hospital-based clinics completed a self-administered survey; medical records were reviewed for demographic and treatment information. Main outcome measure An ANOVA with covariates was performed to measure variation of beliefs and adherence between ethnic groups. Results Mean self-reported adherence in the past week and past month was high (96 %) and the majority of patients (78.5 %) had a viral load <40 copies/mL. Patients had high perceived necessity scores and a low degree of perceived concern with antiretroviral therapy. In our study, treatment beliefs, illness perceptions, and self-reported adherence did not vary between ethnicities (p > 0.05). Conclusion Treatment beliefs, illness perceptions, and adherence appear to be largely similar in English-speaking patients with diverse ethnic backgrounds who have been on treatment for at least 3 months. Strong supports may overcome any cultural differences in treatment beliefs that were expected at the outset.
Literature
1.
go back to reference Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9.PubMedCrossRef Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9.PubMedCrossRef
2.
go back to reference Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med. 2000;133(1):21–30.PubMedCrossRef Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med. 2000;133(1):21–30.PubMedCrossRef
3.
go back to reference Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.PubMedCrossRef Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.PubMedCrossRef
4.
go back to reference Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023–35.PubMed Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023–35.PubMed
5.
go back to reference Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune Defic Syndr. 2008;47(3):397–9.PubMedCrossRef Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune Defic Syndr. 2008;47(3):397–9.PubMedCrossRef
7.
go back to reference Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.PubMedCrossRef Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.PubMedCrossRef
8.
go back to reference Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13(3):185–97.PubMedCrossRef Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13(3):185–97.PubMedCrossRef
9.
go back to reference Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS. 2000;14(2):151–5.PubMedCrossRef Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS. 2000;14(2):151–5.PubMedCrossRef
10.
go back to reference Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386–95.PubMed Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386–95.PubMed
11.
go back to reference Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124–31.PubMed Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124–31.PubMed
12.
go back to reference Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients’ nonadherence to HIV medications. AIDS Patient Care STDS. 2009;23(11):903–14.PubMedCrossRef Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients’ nonadherence to HIV medications. AIDS Patient Care STDS. 2009;23(11):903–14.PubMedCrossRef
13.
go back to reference Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedCentralPubMedCrossRef Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedCentralPubMedCrossRef
14.
go back to reference Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedCrossRef Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedCrossRef
15.
go back to reference Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):117–25.PubMedCrossRef Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):117–25.PubMedCrossRef
16.
go back to reference Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13(9):1099–107.PubMedCrossRef Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13(9):1099–107.PubMedCrossRef
17.
go back to reference Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.PubMed Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.PubMed
18.
go back to reference Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124–33.PubMedCrossRef Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124–33.PubMedCrossRef
19.
go back to reference Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr. 2009;52(2):290–3.PubMedCentralPubMedCrossRef Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr. 2009;52(2):290–3.PubMedCentralPubMedCrossRef
20.
go back to reference Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Int Med. 2007;22(11):1572–8.CrossRef Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Int Med. 2007;22(11):1572–8.CrossRef
21.
go back to reference Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15(1):38–44.PubMedCrossRef Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15(1):38–44.PubMedCrossRef
22.
go back to reference Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The revised Illness Perception Questionnaire (Ipq-R). Psychol Health. 2002;17(1):1–16.CrossRef Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The revised Illness Perception Questionnaire (Ipq-R). Psychol Health. 2002;17(1):1–16.CrossRef
23.
go back to reference Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M. Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med. 2004;59(6):1307–13.PubMedCrossRef Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M. Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med. 2004;59(6):1307–13.PubMedCrossRef
24.
go back to reference Lewis LM, Ogedegbe G. Understanding the nature and role of spirituality in relation to medication adherence: a proposed conceptual model. Holist Nurs Pract. 2008;22(5):261–7.PubMedCrossRef Lewis LM, Ogedegbe G. Understanding the nature and role of spirituality in relation to medication adherence: a proposed conceptual model. Holist Nurs Pract. 2008;22(5):261–7.PubMedCrossRef
25.
go back to reference Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health. 2005;10(4):355–72.PubMedCrossRef Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health. 2005;10(4):355–72.PubMedCrossRef
26.
go back to reference Voyer P, Rail G, Laberge S, Purnell L. Cultural minority older women’s attitudes towards medication and implications for adherence to a medicine regimen. Divers Health Soc Care. 2005;2(1):47–61. Voyer P, Rail G, Laberge S, Purnell L. Cultural minority older women’s attitudes towards medication and implications for adherence to a medicine regimen. Divers Health Soc Care. 2005;2(1):47–61.
27.
go back to reference Grewal K, Stewart DE, Grace SL. Differences in social support and illness perceptions among South Asian and Caucasian patients with coronary artery disease. Heart Lung. 2010;39(3):180–7.PubMedCrossRef Grewal K, Stewart DE, Grace SL. Differences in social support and illness perceptions among South Asian and Caucasian patients with coronary artery disease. Heart Lung. 2010;39(3):180–7.PubMedCrossRef
28.
go back to reference Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity–concerns framework. J Psychosom Res. 2008;64(1):41–6.PubMedCrossRef Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity–concerns framework. J Psychosom Res. 2008;64(1):41–6.PubMedCrossRef
29.
go back to reference Thrasher AD, Earp JA, Golin CE, Zimmer CR. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(1):84–93.PubMedCrossRef Thrasher AD, Earp JA, Golin CE, Zimmer CR. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(1):84–93.PubMedCrossRef
30.
go back to reference van Servellen G, Lombardi E. Supportive relationships and medication adherence in HIV-infected, low-income Latinos. West J Nurs Res. 2005;27(8):1023–39.PubMedCrossRef van Servellen G, Lombardi E. Supportive relationships and medication adherence in HIV-infected, low-income Latinos. West J Nurs Res. 2005;27(8):1023–39.PubMedCrossRef
Metadata
Title
Treatment beliefs, illness perceptions, and non-adherence to antiretroviral therapy in an ethnically diverse patient population
Authors
Mary Gunther
Michelle Foisy
Stanley Houston
Lisa Guirguis
Christine Hughes
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 1/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9866-9

Other articles of this Issue 1/2014

International Journal of Clinical Pharmacy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine